increase the risk of destabilizing a patient's condition, and the panel judged that additional data were needed to understand the frequency of potential problems and concerns associated with switching patients who were stable on an originator TNFi to its biosimilar. Given these concerns, the panel judged that there should be a compelling rationale for switching medications, particularly in light of the marginal cost savings apparent for US patients C. Recommendations for adults with AS-related